Ambeed.cn

首页 / 抑制剂/激动剂 / / / Nalidixic acid sodium salt/萘啶酮酸

Nalidixic acid sodium salt/萘啶酮酸 {[allProObj[0].p_purity_real_show]}

货号:A783659 同义名: 萘啶酸 钠盐

Nalidixic acid sodium salt, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Nalidixic acid sodium salt/萘啶酮酸 化学结构 CAS号:3374-05-8
Nalidixic acid sodium salt/萘啶酮酸 化学结构
CAS号:3374-05-8
Nalidixic acid sodium salt/萘啶酮酸 3D分子结构
CAS号:3374-05-8
Nalidixic acid sodium salt/萘啶酮酸 化学结构 CAS号:3374-05-8
Nalidixic acid sodium salt/萘啶酮酸 3D分子结构 CAS号:3374-05-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Nalidixic acid sodium salt/萘啶酮酸 纯度/质量文件 产品仅供科研

货号:A783659 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

更多 >
产品名称 Topo I Topo II Topo IV Topoisomerase 其他靶点 纯度
Ellagic acid 98%
β-Lapachone 99%+
(s)-10-hydroxycamptothecin 98+%
Camptothecin ++

Topo I, IC50: 0.68 μM

98%
Betulinic acid ++

Eukaryotic topoisomerase I, IC50: 5 μM

98%
Topotecan ++++

Topo I (MCF-7 Luc cells), IC50: 13 nM

Topo I (DU-145 Luc cells), IC50: 2 nM

98%
Irinotecan HCl Trihydrate 98%
SN-38 98%
Levofloxacin hydrate 98%
Dexrazoxane 99%+
Ofloxacin 98+%
Enoxacin 99%+
Flumequine +

Topo II, IC50: 15 μM

98%
Levofloxacin 97%
Etoposide 98%
Pefloxacin mesylate dihydrate 99+%
Marbofloxacin 98+%
Voreloxin HCl 98%
Mitoxantrone 2HCl PKC 98%
Nalidixic acid 98%
Doxorubicin 97%
Novobiocin sodium 95%
Amonafide 99%+
Pirarubicin 98%+
Idarubicin HCl +++

Topo II (MCF-7 cells), IC50: 3.3 ng/mL

99%+
Genistein EGFR 98%
Teniposide 98%
Moxifloxacin 98%
Ciprofloxacin 98%
Clinafloxacin 99%
Gatifloxacin 98%
Daunorubicin HCl +++

DNA synthesis, Ki: 20 nM

98%
Epirubicin HCl 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Nalidixic acid sodium salt/萘啶酮酸 生物活性

描述 Nalidixic acid sodium salt, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria. Nalidixic acid is against with Escherichia coli, Pasteurella spp., Klebsiella pneuiiioniae, Aerobacter aeroyenes, Proteus spp., Salmonella spp., Shigella spp. and Brucella spp. with MIC values of 5.0-12.5 μg/ml, 0.5-2.5 μg/ml, 0.8-25.0 μg/ml, 1.0-25.0 μg/ml, 1.25-30.0 μg/ml, 8-3.2 μg/ml, and 7.5-10.0 μg/ml, respectively. Maximal activity is observed against systemic infections caused by E. coli, A. aerobacter, Proteus mirabilis, Shigella fkxneri, the ED50 values are 25 mg/kg, 60 mg/kg, 50 mg/kg, and 62 mg/kg, respectively. The acute toxicity (LD50) of Nalidixic acid in mice following oral and parenteral administration is: oral, 3300 mg/kg; intravenous, 176 mg/kg; and subcutaneous, 500 mg/kg[3]. The MIC of nalidixic acid was 700 μg/mL against P. aeruginosa. The present findings suggest that the morphology and protein expression of P. aeruginosa is greatly affected by nalidixic acid[4]. Nalidixic acid is metabolized by hydroxylation to 7-hydroxymethylnalidixic acid and then by oxidation to 7-carboxynalidixic acid. The half-lives of the two elimination phases of nalidixic acid are 0.75 and 2.5 h[5].

Nalidixic acid sodium salt/萘啶酮酸 参考文献

[1]G Y LESHER,et al. 1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. J Med Pharm Chem. 1962 Sep;91:1063-5.

[2]Anna Fàbrega, et al. Mechanism of Action of and Resistance to Quinolones. Microb Biotechnol

[3]Fàbrega A, Madurga S, Giralt E, Vila J. Mechanism of action of and resistance to quinolones. Microb Biotechnol. 2009 Jan;2(1):40-61

[4]Al Bahry S, Sivakumar N, Al-Khambashi M. Effect of nalidixic acid on the morphology and protein expression of Pseudomonas aeruginosa. Asian Pac J Trop Med. 2012 Apr;5(4):265-9

[5]Vree TB, Wijnands WJ, Baars AM, Hekster YA. Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation. Pharm Weekbl Sci. 1988 Oct 14;10(5):193-9

Nalidixic acid sodium salt/萘啶酮酸 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.93mL

0.79mL

0.39mL

19.67mL

3.93mL

1.97mL

39.34mL

7.87mL

3.93mL

Nalidixic acid sodium salt/萘啶酮酸 技术信息

CAS号3374-05-8
分子式C12H11N2NaO3
分子量 254.22
SMILES Code CCN1C=C(C(C2=C1N=C(C=C2)C)=O)C([O-])=O.[Na+]
MDL No. MFCD00064376
别名 萘啶酸 钠盐
运输蓝冰
InChI Key ROKRAUFZFDQWLE-UHFFFAOYSA-M
Pubchem ID 3864541
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Inert atmosphere, room temperature

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。